Immunovant Stock: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy (IMVT)
· seekingalpha.com
Initiate coverage of Immunovant (IMVT) with a BUY and $50 price target based on IMVT-1402’s best-in-class IgG reduction and ~$4B peak sales outlook. See more.
Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU ...